Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3976704 | Brachytherapy | 2015 | 8 Pages |
Abstract
BT boost was associated with a moderate reduction to PCSM in men with localized unfavorable-risk prostate cancer. Those most likely to benefit are younger patients with high-risk disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Michael Xiang, Paul L. Nguyen,